NDAIMPLANTATIONIMPLANT
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 26m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOLADEX (goserelin) is a gonadotropin-releasing hormone (GnRH) agonist administered as a subcutaneous implant for hormone-sensitive cancers and endometriosis. It suppresses testosterone and estrogen production by downregulating pituitary GnRH receptors. The drug is indicated in prostate cancer, breast cancer, and endometriosis across various treatment contexts.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team restructuring and emphasis on cost management and market defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
Started Jun 2026
88 enrolled
Advanced Breast Cancer
Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
Started May 2026
132 enrolled
Aplastic Anaemia (AA)Allogeneic Haematopoietic Stem Cell TransplantationOvarian Insufficiency
Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin
Started May 2026
64 enrolled
Ovarian InsufficiencyAutologous Hematopoietic Stem Cell Transplantation
Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin
Started May 2026
64 enrolled
Allogeneic Haematopoietic Stem Cell TransplantationMalignant Hematologic DiseaseOvarian Insufficiency
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Started May 2023
24 enrolled
Prostate Cancer
Worked on ZOLADEX at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.